Revolutionary Biomedical Technologies for Life-Critical Applications

Pioneering three transformative biotechnologies that address critical unmet needs in emergency medicine, chronic disease management, and advanced robotics.

Explore Our Technologies
$45B+
Global Market Opportunity
3
Breakthrough Technologies
18
Months to Clinical Trials

Our Technology Platform

Three breakthrough solutions leveraging biocompatible materials, miniaturized life-support systems, and tissue engineering to create life-saving medical innovations.

Oxygen Reserve Unit

An implantable or wearable emergency oxygen system that automatically delivers supplemental oxygen when blood oxygen levels drop below safe thresholds.

The ORU stores concentrated oxygen in a biocompatible titanium alloy housing and activates automatically during respiratory crises, providing 16 minutes of life-saving oxygen delivery through an integrated catheter network.

Target Patient Population 16 million Americans with chronic obstructive pulmonary disease, plus patients with severe asthma, pulmonary fibrosis, and other conditions causing sudden respiratory failure.

Secondary Cardiac Reserve System

A miniaturized mechanical pump that provides emergency cardiac support during acute heart failure events, maintaining adequate circulation for 30 to 45 minutes.

The system remains dormant during normal cardiac function but activates automatically when sensors detect insufficient cardiac output, providing crucial time for emergency transport and definitive intervention.

Addressable Market 6 million Americans with heart failure and 800,000 individuals who experience heart attacks annually at risk of sudden cardiac death.

BioSkin Artificial Tissue Platform

Genuine bioengineered human skin with integrated muscle tissue for medical grafting and advanced robotic applications.

Our revolutionary growth-based process produces living human skin that integrates seamlessly for burn victims and trauma patients, while providing authentic biological properties for prosthetic limbs, surgical robots, and humanoid systems.

Market Segments $8 billion wound care and skin graft market with 9% annual growth, plus $15 billion surgical robotics opportunity expanding at 22% annually.

Market Opportunity

Addressing substantial markets with accelerating demand driven by aging populations, increasing chronic disease prevalence, and advancing medical technology.

$28B
Respiratory Support Devices
$25B
Cardiac Rhythm Management
$20B
Wound Care & Skin Substitutes
$15B
Surgical Robotics Systems

Investment Highlights

A platform technology company with proven capabilities, established regulatory pathways, and transformative medical solutions.

Functional Prototypes

All three technologies have achieved functional prototype status with successful in vitro testing and early validation studies.

Clear Regulatory Path

Established FDA approval pathways with experienced regulatory consultants and preliminary agency discussions underway.

Clinical Partnerships

Advisory boards and collaborative relationships with leading academic medical centers for clinical validation.

Strong IP Portfolio

Provisional patents filed covering core aspects of device architecture, manufacturing processes, and control systems.

Scalable Business Model

Hybrid commercialization strategy combining strategic partnerships with major medical device companies and direct manufacturing.

Experienced Team

Deep expertise in biomedical engineering, emergency medicine, regulatory affairs, and commercial medical device operations.